B

Bicara Therapeutics Inc
NASDAQ:BCAX

Watchlist Manager
Bicara Therapeutics Inc
NASDAQ:BCAX
Watchlist
Price: 17.6 USD -0.23% Market Closed
Market Cap: 964.1m USD

Operating Margin
Bicara Therapeutics Inc

0%
Current
0%
Average
-4.2%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
0%
=
Operating Profit
-141.1m
/
Revenue
0

Operating Margin Across Competitors

No Stocks Found

Bicara Therapeutics Inc
Glance View

Market Cap
961.2m USD
Industry
Biotechnology

Bicara Therapeutics, Inc. is a clinical-stage biotechnology company and it developing first-in-class biologics engineered to combine the precision of well validated, tumor-targeting antibodies with the power of tumor microenvironment modulators. The company is headquartered in Boston, Massachusetts and currently employs 32 full-time employees. The company went IPO on 2024-09-13. Its lead program, ficerafusp alfa, is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor (EGFR), directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b). Through this dual-targeting mechanism, ficerafusp alfa has the potential to exert potent anti-tumor activity by simultaneously blocking both cancer cell-intrinsic EGFR survival and proliferation and the immunosuppressive TGF-b signaling within the tumor microenvironment. Ficerafusp alfa is initially being developed in head and neck squamous cell carcinoma, where there remains a significant unmet need. Its platform is designed to facilitate the development of bifunctional therapies that precisely target the tumor and deliver a tumor-modulating payload to the tumor site.

BCAX Intrinsic Value
Not Available
B
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
0%
=
Operating Profit
-141.1m
/
Revenue
0
What is the Operating Margin of Bicara Therapeutics Inc?

Based on Bicara Therapeutics Inc's most recent financial statements, the company has Operating Margin of 0%.

Back to Top